Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-295S1 in Advanced Malignant Solid Tumors
NCT04908046Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HMPL-295 in malignant solid tumor, sponsored by HUTCHMED. Primary endpoints: Safety and tolerability of oral HMPL-295S1 monotherapy, Maximum Tolerated Dose and 1 more. Started May 2021; status: completed.
02
Drugs
HMPL-295
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT04908046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908046.